Do elevated levels of Interleukin-1 beta (IL-1β) and Interleukin-18 (IL-18) indicate NLRP3 (Nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3) activation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Elevated levels of Interleukin-1 beta (IL-1β) and Interleukin-18 (IL-18) are indicative of NLRP3 (Nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3) activation.

Key Findings

  • The activation of the NLRP3 inflammasome leads to the cleavage of pro-IL-1β and pro-IL-18, resulting in the production of mature IL-1β and IL-18 1.
  • Elevated levels of IL-1β and IL-18 have been observed in various conditions, including ischemic stroke and macrophage activation syndrome (MAS), which are associated with NLRP3 activation 1.
  • The NLRP3 inflammasome can be activated by various stimuli, including mitochondrial dysfunction, oxidative stress, and the release of mitochondrial DNA (mtDNA) into the cytosol 1.

NLRP3 Activation Mechanism

  • The NLRP3 inflammasome is a multiprotein complex that plays a crucial role in the innate immune response 1.
  • The activation of NLRP3 leads to the recruitment of caspase-1, which cleaves pro-IL-1β and pro-IL-18, resulting in the production of mature IL-1β and IL-18 1.
  • Elevated levels of IL-1β and IL-18 can contribute to inflammation and tissue damage in various diseases, including ischemic stroke and MAS 1.

Clinical Implications

  • The measurement of IL-1β and IL-18 levels may be useful in diagnosing and monitoring diseases associated with NLRP3 activation, such as MAS 1.
  • Therapeutic strategies targeting the NLRP3 inflammasome and IL-1β and IL-18 production may be effective in reducing inflammation and tissue damage in these diseases 1.

From the Research

NLRP3 Activation and IL-1β and IL-18 Levels

  • Elevated levels of Interleukin-1 beta (IL-1β) and Interleukin-18 (IL-18) are associated with NLRP3 (Nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3) activation, as they are both pro-inflammatory cytokines that are processed and secreted upon activation of the NLRP3 inflammasome 2, 3, 4, 5, 6.
  • The NLRP3 inflammasome is a multiprotein complex that activates caspase-1, leading to the processing and secretion of IL-1β and IL-18, which have both shared and unique biological functions 2, 3, 4, 5.
  • The ratio between IL-1β and IL-18 can be used to describe the NLRP3 inflammasome response, as different stimuli can induce different ratios of these cytokines 2.

Mechanism of NLRP3 Activation

  • The mechanism of NLRP3 activation involves the generation of reactive oxygen species (ROS), which is a crucial element for NLRP3 activation 3.
  • The NLRP3 inflammasome can be activated by diverse stimuli, including microorganisms and metabolic dysregulation, and its activation leads to the maturation of IL-1β and IL-18 and the induction of pyroptosis, a form of cell death 3, 5.

Clinical Implications

  • Elevated levels of NLRP3, IL-1β, and IL-18 have been observed in patients with diabetic nephropathy, and their levels increase with the aggravation of the disease 6.
  • The plasma levels of NLRP3, IL-1β, and IL-18 can be useful as indicators of the occurrence and development of diabetic nephropathy and can provide clinical guidance for the early diagnosis and treatment of the disease 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.